AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02042404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound amplification provided via EarLens System.
Description: The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
Study NCT04138004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol in combination with lubiprostone
Description: 2-litre polyethylene glycol split-dose in combination with one 24 mcg tablet of lubiprostone
Study NCT02996695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Artesunate is a succinic ester of artemether.
Study NCT02996695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artesunate
Description: Artesunate is a succinic ester of artemether.
Study NCT02996695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: 4-aminoquinolone, antimalarial agent for oral administration
Study NCT04138004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol alone
Description: 4-litre polyethylene glycol split-dose
Study NCT02996695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine
Description: 4-aminoquinolone, antimalarial agent for oral administration
Study NCT02996695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ (NF54) Challenge
Description: Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
Study NCT02996695 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ (NF54) Challenge
Description: Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
Study NCT03761667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopy using Narrow band imaging
Description: Inspection of resection margin of SSA/P for the evaluation of complete resection or the presence of remnant lesion using NBI method
Study NCT00369122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00369122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04167384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette
Study NCT04167384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® Mint 4 mg nicotine lozenge
Study NCT04167384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1903-11, a hard nicotine lozenge, 2 mg nicotine
Study NCT04167384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1903-11, a hard nicotine lozenge, 4 mg nicotine
Study NCT04167384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1903-11, a hard nicotine lozenge, 8 mg nicotine
Study NCT04167384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: CSD1903-12, a soft nicotine lozenge, 2 mg nicotine
Study NCT00369122 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT00369122 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy
Study NCT01072669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ambrisentan
Description: Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily\[if the lower dose is tolerated\] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
Study NCT01072669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ambrisentan
Description: Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily\[if the lower dose is tolerated\] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
Study NCT04167384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: CSD1903-12, a soft nicotine lozenge, 4 mg nicotine
Study NCT00808678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: once, see arm description for more information
Study NCT00808678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: once, see arm description for more information
Study NCT00808678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: once, see arm description for more detail
Study NCT04167384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product H
Description: CSD1903-12, a soft nicotine lozenge, 8 mg nicotine
Study NCT02102932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg empagliflozin/850 mg metformin FDC
Description: 5 mg empagliflozin/850 mg metformin FDC
Study NCT02102932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg empagliflozin
Description: 10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
Study NCT02102932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg empagliflozin
Description: 10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
Study NCT02102932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 850 mg metformin
Description: 850mg metformin tablet
Study NCT02102932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg empagliflozin
Description: 5 mg empagliflozin
Study NCT02102932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 850 mg metformin
Description: 850 mg metformin
Study NCT02102932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg empagliflozin/850 mg metformin FDC
Description: 12.5 mg empagliflozin/850 mg metformin FDC
Study NCT04171765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.
Study NCT04171765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFKB8488A
Description: Participants will receive subcutaneous (SC) BFKB8488A.
Study NCT01341197 — intervention group
Intervention type: OTHER
Intervention: Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test
Study NCT02224092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multivitamin multimineral with phytonutrient supplementation
Description: The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo.
Study NCT02224092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: multivitamin multimineral with phytonutrient supplementation
Description: The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo.
Study NCT03595774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beet root juice
Description: Beet root juice
Study NCT03595774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beet root juice
Description: Beet root juice
Study NCT04558580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide
Description: Rufinamide
Study NCT04612582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Bortezomib (d 1, 8, 15, 22, 1.3mg /m2, subcutaneous injection); thalidomide (d 1-28 50-100mg, oral); dexamethason (d 1, 2, 8, 9, 15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, the patients will complete six courses of treatment after entering the group, and the total observation time is one year after the end of treatment.
Study NCT04612582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Bortezomib (d 1, 8, 15, 22,1.3mg / m2, subcutaneous injection); cyclophosphamide (d 1, 2,900mg / m2, intravenous drip); dexamethason (d 1, 2, 8, 9,15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, patients will complete six courses of treatment after entering the group, the overall observation time is one year after the end of treatment.
Study NCT01385761 — intervention group
Intervention type: DEVICE
Intervention: Laryngeal Mask Airway
Description: Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
Study NCT01385761 — intervention group
Intervention type: DEVICE
Intervention: air-QTM Intubating Laryngeal Airway
Description: Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
Study NCT04186936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Caplet with Loperamide HCl and Simethicone
Description: Participants will receive combination caplet with loperamide HCl 2 mg and simethicone 125 mg as Test product A per assigned treatment sequence.
Study NCT02102932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg empagliflozin/500 mg metformin FDC
Description: 12.5 mg empagliflozin/500 mg metformin FDC
Study NCT02102932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg empagliflozin/500 mg metformin FDC
Description: 5 mg empagliflozin/500 mg metformin FDC
Study NCT02102932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg metformin
Description: 500 mg metformin
Study NCT04186936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide HCl
Description: Participants will receive loperamide HCl 2 mg tablet-lyophilizate orally as part of Reference product B per assigned treatment sequence.
Study NCT04186936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: Participants will receive Simethicone 40 mg capsule orally as part of Reference product B per assigned treatment sequence.
Study NCT01556880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS)
Description: A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
Study NCT03388515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SSS11
Description: IV infusion for 60 min.
Study NCT03388515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: IV infusion for 60 min.
Study NCT01676727 — intervention group
Intervention type: DEVICE
Intervention: CoreValve aortic valve
Description: Implantation of CoreValve aortic valve via direct aortic approach
Study NCT03200184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir and daclatasvir
Description: A fixed dose combination pill containing 400mg sofosbuvir and 60 mg daclatasvir given daily for 12 weeks. If a patient is cirrhotic, treatment duration would be 24 weeks.
Study NCT00476359 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lopinavir/r plus saquinavir
Description: lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily
Study NCT04091009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Participants will be randomly assigned to be maintained on their daily dose of buprenorphine or to have their buprenorphine reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided
Study NCT04091009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided
Study NCT01919619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01919619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT03985111 — intervention group
Intervention type: DEVICE
Intervention: Central Venous Catheter
Description: Insertion of a central venous catheter insertion pre-operatively (electively)
Study NCT04130984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZ-IO
Description: The insertion site locates at 1 cm medial tibial tuberosity. EZ-IO (U.S. Teleflex® Corporation) will be used with an adult 15G needle. Pull out the needle when having a sense of frustration, withdraw the bone marrow with the syringe, bolus 20 mL of normal saline to open intramedullary path and begin drug resuscitation at the same time. The retention time of IO route should be less than 24 h, and venous access should be established after winning rescue time as soon as possible to continue treatment.
Study NCT00580970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovastatin
Description: The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
Study NCT04056351 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Post-Operative (OP) Computer Tomography (CT)
Description: Post-OP CT of the treated shoulder
Study NCT04056351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires on patient activity and comorbidities
Description: * Shoulder activity scale (Marx)~* Parker Mobility Scale~* Barthel index~* Charlson Comorbidity Score
Study NCT04056351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Grip strength measurement
Description: Grip strength will be measured using a CE marked hydraulic hand dynamometer device.
Study NCT04056351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-invasive shoulder activity tracking usinig wearable sensors
Description: Post-OP activity will be assessed via wearable CE-marked accelerometer sensors.
Study NCT03265301 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hysteroscopy
Description: Includes Video set up, mini-hysteroscope system, continuous inflow and outflow, rod lens or fiber optic lens Zero to 30 degree angle and mechanical instruments (Scissors,Graspers , Cup biopsy forceps and bipolar instruments)
Study NCT03265301 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Office hysteroscopy
Description: will be done in out patient clinic without anesthesia
Study NCT03265301 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional hysteroscopy
Description: will be done in operative room under general anesthesia
Study NCT01808248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Study NCT01808248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
Study NCT04238715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Description: E7090 tablets orally.
Study NCT03193567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEKT cell
Description: 3 cycles of HEKT cell treatment
Study NCT02338622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: olaparib BD
Study NCT02338622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: AZD5363 BD
Study NCT00689078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1%
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
Study NCT00689078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 0.12%
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
Study NCT00689078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol Etabonate 0.2%
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
Study NCT00689078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
Study NCT00773929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-593
Description: Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.~Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety
Study NCT04284852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: PARP inhibitor
Study NCT01147640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-101/ tazobactam and metronidazole
Description: CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
Study NCT01147640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem plus saline placebo
Description: meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
Study NCT01826721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transplant Medication Information Teaching Tool
Description: Online e-learning tool for post-transplant medication education.
Study NCT01017471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited incision using PSU retractor
Description: carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
Study NCT00658580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin + etoposide
Description: Cisplatin 90 mg/m² day 1, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks
Study NCT00658580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin + ifosfamide + etoposide
Description: Epirubicin 60 mg/m² day 1, every 3 weeks~Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks
Study NCT03425513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis B serology
Description: A serum specimen will be taken and assessed for hepatitis B serology (HBsAg and anti-HBc antibodies).